June 9, 2022 03:23 PM EDT

#BIO22: By the Numbers: After the music died, you can see some encouraging signs on the M&A and licensing fronts. But where's the big buy-in?

John Carroll

Editor & Founder

It’s clear from #ASCO22 that biopharma audiences are back, live, at the big conferences. That’s encouraging, as we return to more face-to-face meetings to advance …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#BIO22: By the Numbers: After the music died, you can see some encouraging signs on the M&A and licensing fronts. But where's the big buy-in?

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

#BIO22: By the Num­bers: Af­ter the mu­sic died, you can see some en­cour­ag­ing signs on the M&A and li­cens­ing fronts. But where's the big buy-in?

Editor & Founder

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

#BIO22: By the Numbers: After the music died, you can see some encouraging signs on the M&A and licensing fronts. But where's the big buy-in?